Indicated in pediatrics (6-11 years old)
for moderate-to-severe atopic dermatitis

DUPIXENT® (dupilumab injection) is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
DUPIXENT® can be used with or without topical corticosteroids.


† The safety of DUPIXENT® was assessed in a trial of 367 patients 6 to 11 years of age with severe atopic dermatitis (AD-1652) through Week 16. The longer-term safety of DUPIXENT® + TCS was assessed in a 52-week open-label extension study including 368 subjects 6 to 11 years of age with atopic dermatitis (AD-1434) who had participated in a prior atopic dermatitis study of DUPIXENT®. Among subjects who entered this study, 110 (29.9%) had moderate, and 72 (19.6%) had severe atopic dermatitis at the time of enrolment.1



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo